



1 Article

2 **Social patterning and stability of intention to accept a**
3 **COVID-19 vaccine in Scotland: Will those most at**
4 **risk accept a vaccine?**

5 Lynn Williams^{1*}, Paul Flowers¹, Julie McLeod¹, David Young¹, Lesley Rollins¹ and the
6 CATALYST project team¹

7 ¹ University of Strathclyde, Glasgow, UK

8 * Correspondence: lynn.williams@strath.ac.uk

9 Received: date; Accepted: date; Published: date

10 **Abstract:** Vaccination is central to controlling COVID-19. Its success relies on having safe and
11 effective vaccines and also on high levels of uptake by the public over time. Addressing questions
12 of population-level acceptability, stability of acceptance and sub-population variation in
13 acceptability are imperative. Using a prospective design, a repeated measures two-wave online
14 survey was conducted to assess key sociodemographic variables and intention to accept a
15 COVID-19 vaccine. The first survey (time 1) was completed by 3436 people during the period of
16 national lockdown in Scotland and the second survey (n = 2016) was completed two months later
17 (time 2) when restrictions had been eased. At time one, 74% reported being willing to receive a
18 COVID-19 vaccine. Logistic regression analyses showed that there were clear sociodemographic
19 differences in intention to accept a vaccine for COVID-19 with intention being higher in
20 participants of white ethnicity in comparison to Black, Asian, and minority ethnic (BAME) groups,
21 and in those with higher income levels and higher education levels. Intention was also higher in
22 those who were ‘shielding’ due to underlying medical conditions. Our results suggest that future
23 interventions such as mass media and social marketing need to be targeted to a range of
24 sub-populations and diverse communities.

25 **Keywords:** COVID-19; vaccination; vaccine hesitancy; interventions; social patterning; inequalities

26

27 **1. Introduction**

28 Vaccination will be vitally important in controlling future waves of the COVID-19 pandemic.
29 Despite uncertainty regarding the specifics of many of the potential vaccines (e.g. efficacy and
30 required doses), it is clear that high levels of overall public acceptance will be required. In recent
31 years, vaccination rates have fallen and public confidence in vaccines is inconsistent [1-4]. The term
32 ‘vaccine hesitancy’ refers to the ‘delay in acceptance or refusal of vaccines despite availability of
33 vaccine services’ [5, 6]. The reasons for vaccine hesitancy are multi-levelled and complex, involving
34 psychological, social and contextual factors [7-9]. Vaccine hesitancy was evident during the H1NI
35 pandemic, which saw variable vaccine uptake, with non-uptake related to concerns about vaccine
36 safety and perceptions of threat and risk [10-14]. Preliminary evidence from the current pandemic
37 suggests that a sizable proportion of the public are currently either undecided or unwilling to
38 receive a future vaccine for COVID-19 [15-20]. The importance of high levels of uptake was
39 demonstrated in a recent study which suggests that in order to “extinguish an ongoing epidemic”,
40 the efficacy of a vaccine as the sole intervention needs to be at least 80% when uptake is at 75%. If
41 uptake is lower than this then an even more efficacious vaccine would be needed [21].

42 A recent global survey from Ipsos MORI [18], conducted in July and August 2020, of 20,000
43 adults from 27 countries found that 74% of people would get a vaccine if it was available. However,

44 only 37% strongly agree that they would want to get it, while 37% somewhat agree. Large variations
45 in acceptance levels were also shown across countries, ranging from 97% in China, to 54% in Russia.
46 The primary reason that people gave for not wanting to accept the vaccine was worry about the side
47 effects, followed by concern about the effectiveness of a vaccine, and not feeling at risk of contracting
48 COVID-19 [18].

49 Emerging research also suggests that particular sub-populations have lower acceptance
50 intentions. In France, during late March 2020, 26% of the sample reported that they would not accept
51 a vaccine. COVID-19 vaccination hesitancy was more prevalent in those with low income, young
52 women, and among older adults aged 75+, and it was associated with political views [19]. In
53 Australia, more positive views were reported in April shortly after the introduction of lockdown,
54 with 4.9% stating they would not get the vaccine, and 9.4% stating indifference. Here, COVID-19
55 vaccination hesitancy was associated with lower education levels and health literacy, and the belief
56 that the threat of COVID-19 had been exaggerated [20]. A study conducted two months later in
57 Australia, when restrictions had been eased, found that those who were unwilling or unsure about
58 accepting a COVID-19 vaccine had increased by 10% [16], suggesting that COVID-19 vaccination
59 levels may fluctuate depending on the context of infection rates and restrictions. A further study
60 from the US reports an acceptance level of 67% and found that acceptance levels were lower in
61 unemployed participants and in Black American participants [17].

62 Together, these initial studies suggest that COVID-19 vaccine acceptance differs both across
63 countries and in different sub-populations within countries. The research to-date has been based on
64 cross-sectional designs and has not yet explored how intention to accept a COVID-19 vaccine may
65 change in line with rates of infection or lockdown restrictions within the same sample. We explored
66 this question of intention to vaccinate against COVID-19 in a prospective survey in Scotland at two
67 time points (during national lockdown and during the easing of restrictions). The present study has
68 three key research questions (RQs):

69 RQ1: What proportion of people would accept a vaccine for COVID-19?

70 RQ2: Is COVID-19 vaccine acceptance stable over time in the context of different infection levels
71 and restrictions?

72 RQ3: What socio-demographic factors are associated with intention to accept a future vaccine
73 for COVID-19?

74 2. Materials and Methods

75 The present study consisted of an online survey at two time points. The first survey (time one)
76 was conducted during lockdown restrictions (20th May- 12th June 2020, weeks 9-12 of national
77 lockdown). The second survey (time two) was conducted two months later (during August 2020)
78 when lockdown restrictions in Scotland had been eased and there was little community transmission.
79 Ethical approval was received from the University of Strathclyde Ethics Committee (Ref:
80 61/05/05/2020/A Williams) prior to commencement of the study. The data reported here are part of
81 the larger CATALYST project which examined the changes that people had experienced during
82 lockdown.

83 2.1. Participants and procedure

84 For time one, participants were recruited with convenience sampling through advertisements
85 on social media, including Facebook and Twitter, which directed participants to Qualtrics where
86 they could access the online questionnaire. Included in the survey for time one was an information
87 sheet and consent form which participants read and signed before completing the survey. For time
88 two, participants were re-contacted via email and provided with a Qualtrics link to the online
89 questionnaire, inviting them to take part at time two.

90 2.2. Questionnaire

91 2.2.1. Demographics and Health

92 Participants provided self-reported sociodemographic and health data at time one for the
93 following variables: age (18-49, 50+); gender (female, male); ethnicity (white, BAME); annual
94 household income (<£16,000, £16,000 – £29,999, £30,000 - £59,999, £60,000+); level of education (no
95 qualifications/left school at 16, high school/college, university) and risk group/shielding status (i.e.
96 those who had been classified as high risk based on underlying health conditions or age) (yes/no).

97 2.2.2. COVID-19 vaccination intention

98 Intention to be vaccinated for COVID-19 was measured by self-report at time one and again at
99 time two. Participants were asked “If a vaccine for Coronavirus (Covid-19) becomes available,
100 would you want to receive it?” and provided response options “I *definitely* would not want to receive
101 it”, “I *probably* would not want to receive it”, “Unsure”, “I *probably* would want to receive it” and “I
102 *definitely* would want to receive it”.

103 2.3. Statistical Analysis

104 The COVID-19 vaccination intention response options of “I definitely would not want to receive
105 it”, “I probably would not want to receive it”, and “Unsure” were coded as “Vaccine Hesitant” and
106 the options “I probably would want to receive it” and “I definitely would want to receive it” were
107 coded as “Vaccine Willing” to create dichotomous “willing” versus “hesitant” variables. Frequency
108 responses to the vaccination intention questions were calculated (RQ1). In addition, a McNemar’s
109 test was used to examine any changes in vaccine willingness across the two time points from
110 lockdown (time 1) to the easing of restrictions (time 2) for those participants who completed the
111 survey at both time points (RQ2). Univariate and multivariate logistic regression analyses were
112 carried out to examine the socio-demographic factors associated with COVID-19 vaccination
113 intention at time 1 (we selected time 1 intention as the dependent variable in order to maximise
114 sample size) (RQ3). Due to issues relating to the representativeness of our sample and specifically
115 the under-representation of males and those with lower levels of educational attainment (as shown
116 in Table 1), we carried out post-stratification weighting of these variables based on the Scottish
117 census data to correct for these imbalances. All of the analyses that we report are based on this
118 weighed data in order to allow for greater extrapolation of the results to the Scottish population. All
119 analyses were conducted using IBM SPSS Statistics (version 25) at 5% significant levels.

120 3. Results

121 Overall, 3436 participants (79% female) residing in Scotland, aged over 18, were recruited for
122 the current study. The sample was comprised of participants aged between 18 and 92 ($M = 46.21$, SD
123 $= 15.26$). Of the original sample, 2016 participants took part at time 2, representing a 59% follow-up
124 rate. We compared the socio-demographic characteristics of those who participated in both waves of
125 the survey with those who dropped out. There were no significant differences between the
126 completers and non-completers based on ethnicity, income, or high risk status but the groups did
127 differ significantly on education level, gender, and age with higher dropout in those with lower
128 education levels, males, and in the younger age group. Participant socio-demographic characteristics
129 from time one and time two from our original sample (not weighted) are shown in Table 1.

130 **Table 1.** Sociodemographic and health variables for the sample at time 1 and time 2.

Variables	Time 1		Time 2	
	n	%	n	%
Age				
18-49	1847	53.8	974	48.3
50+	1578	45.9	1034	51.5
Gender				
Female	2719	79.1	1632	82.1
Male	666	19.4	355	17.9
Ethnicity				

White	3308	96.3	1949	96.7
BAME	101	2.9	52	2.6
<i>Household Income</i>				
<£16,000	334	9.7	196	9.7
£16,000 - £29,999	611	17.8	348	17.3
£30,000 - £59,000	1203	35.0	717	35.6
£60,000+	902	26.3	519	25.7
<i>Education Level</i>				
No quals/left school 16	168	4.9	77	3.8
High School/College	780	22.7	439	21.8
University	2435	70.9	1467	72.8
<i>High risk/Shielding</i>				
Yes	508	14.8	316	15.7
No	2855	83.1	1677	83.2

131 Note. % calculations includes missing data.

132

133 3.1. RQ1: What proportion of people would accept a vaccine for COVID-19?

134 A frequency analysis of the proportion of participants that reported willingness and hesitancy
 135 to accept a COVID-19 vaccine across the two time points are shown in Table 2. At time 1, 74% of
 136 participants were willing to receive a COVID-19 vaccine, and at time 2 this figure was slightly higher
 137 at 78% (note that the numbers reported in Table 2 for the 'vaccine hesitant' and 'vaccine willing'
 138 rows are based on the total sample, whereas the other numbers in the table are based upon only
 139 those participants who completed the questionnaire at both time points).

140 3.2. RQ2 – Is COVID-19 vaccine acceptance stable over time in the context of different infection levels and
 141 restrictions?

142 Table 2 presents the results relating to stability of COVID-19 vaccination intention for those
 143 participants who completed the questionnaire at both time points. McNemar's test on these
 144 participants showed that there had been a significant shift in vaccine intention over time, ($p=.004$). Of
 145 the 54 participants who reported that they definitely would not want vaccinated at time 1, 13 (24.1%)
 146 reported that they would now accept the vaccine at time 2. Of the 79 who reported that they
 147 probably would not want the vaccine at time 1, 12 of them (15.2%) would now accept the vaccine at
 148 time 2. Of the 301 who were unsure, 113 (37.5%) reported at time 2 that they would now accept the
 149 vaccine. Of the 904 people who initially would definitely want to be vaccinated, 20 (2.2%) would
 150 now not take it, and 10 (1.1%) were now unsure. In addition, of the 498 who initially probably would
 151 receive it, 13 would now not take it (2.6%) and 72 are now unsure (14.5%).

152 **Table 2.** Intention to accept a COVID-19 vaccine at time 1 and time 2.

COVID-19 vaccine intention	Time 1 (national lockdown)		Time 2 (easing of restrictions)	
	N	%	N	%
I definitely would not want to receive it	54	3%	65	4%
I probably would not want to receive it	79	4%	84	5%
Unsure	301	17%	262	14%
I probably would want to receive it	498	27%	506	27%
I definitely would want to receive it	904	49%	919	50%
Vaccine Hesitant	850	26%	416	22.5%
Vaccine Willing	2406	74%	1433	77.5%

153 3.3. RQ3: What socio-demographic and health factors are associated with intention to accept a future vaccine
 154 for COVID-19?

155 As shown in Table 3, univariate logistic regression analyses showed that there was a significant
156 effect of age, ethnicity, education level, household income and high risk/shielding status on
157 intention to accept a COVID-19 vaccine. There was no effect of gender on intention to accept a
158 COVID-19 vaccine. In relation to age, younger participants reported higher levels of intention than
159 those in the older age group. We also found that participants of white ethnicity had higher levels of
160 intention than those from BAME groups. In relation to education, those with higher levels of
161 education had higher levels of intention to receive the vaccine. In addition, those with higher levels
162 of annual household income had higher intention levels than those with lower income levels. Finally,
163 those participants at high risk or in the shielding category had higher levels of intention than those
164 not in this group.
165

166 **Table 3.** Univariate analysis of socio-demographic factors and intention to accept a COVID-19
167 vaccine.

Variable	p-value	Comparison	Coefficient	p-value
Age	<0.001	50+ vs. 18-49	0.70	-
Gender	0.190	Male vs. Female	1.11	-
Ethnicity	0.018	White vs. BAME	1.72	-
Education	<0.001	High school/College vs. No qualifications/left at 16	1.98	<0.001
		University vs. No qualifications/left at 16	2.78	<0.001
Household income	<0.001	£16000 - £29999 vs. <£16000	1.11	0.441
		£30000 - £59999 vs. <£16000	1.39	0.009
		£60000+ vs. <£16000	1.97	<0.001
High risk/Shielding	0.012	Yes vs. No	1.31	-

168 For the multivariate logistic regression we entered those variables that were significant in the
169 univariate analysis (i.e. age, ethnicity, education, household income, and high risk/shielding).
170 Ethnicity, education, household income and high risk remained significantly associated with
171 intention to receive a COVID-19 vaccine in the multivariate analysis, but age was no longer
172 significant. When considering the coefficients (see Table 4), those participants of white ethnicity are
173 almost three times as likely to accept a COVID-19 vaccine compared to those from BAME groups.
174 Similarly, those from the highest education group are two and a half times more likely than those
175 from the lowest education group to accept it, and those in the highest income group are 1.82 times
176 more likely to accept the vaccine compared to those in the lowest income group. In addition,
177 those in a high risk/shielding group are almost twice as likely to accept a COVID-19 vaccine
178 compared to those not in a high risk/shielding group.

179 **Table 4.** Multivariate analysis of socio-demographic factors and intention to accept a COVID-19
180 vaccine.

Variable	p-value	Comparison	Coefficient	95% CI	p-value
Ethnicity	<0.001	White vs. BAME	2.91	1.75-4.81	-
Education	<0.001	High school/College vs. No qualifications/left at 16	1.90	1.56-2.32	<0.001
		University vs. No qualifications/left at 16	2.50	1.95-3.21	<0.001
Household income	<0.001	£16000 - £29999 vs. <£16000	1.05	0.80-1.38	0.743
		£30000 - £59999 vs. <£16000	1.27	0.98-1.65	0.077
		£60000+ vs. <£16000	1.82	1.35-2.45	<0.001
High risk/Shielding	<0.001	Yes vs. No	1.95	1.53-2.49	-

181 4. Discussion

182 The present study is the first to examine intention to accept a COVID-19 vaccine in Scotland.
183 The study also extends existing research that has examined acceptance levels in other countries by
184 adopting a prospective design, allowing us to examine stability in vaccine intentions over time
185 within the same sample. We found that 74% of the sample at time 1 intended to receive a COVID-19
186 vaccine (during the period of national lockdown). Interestingly, two-months later, intention levels
187 had shifted significantly. The greatest shift in intention levels was apparent in the group who were
188 “Unsure” at time one, with 38% of those participants now saying they would accept a vaccine. The
189 second survey was carried out when restrictions had been eased and there was little transmission of
190 COVID-19, it is therefore notable that intention to receive a COVID-19 vaccine was still high at this
191 time. Stability in intention to receive a COVID-19 vaccination will be particularly important given
192 that two doses of the vaccine are likely to be needed over time.

193 Our findings suggest that although the majority of respondents in Scotland indicated that they
194 would want to receive a COVID-19 vaccine, there is a sizable minority of the public who were
195 hesitant about receiving a vaccine, mirroring the overall picture that is emerging from other
196 countries. Indeed, the intention levels reported here are similar to those emerging globally from the
197 recent Ipsos survey in which 74% of people overall said they would get a COVID-19 vaccine [18].

198 We also found that intention to accept a COVID-19 vaccination varied by sub-population. There
199 was a significant effect of ethnicity, education level, household income and high risk/shielding status
200 on intention to accept a COVID-19 vaccine. Of particular note, those of white ethnicity are nearly
201 three times as likely to accept a COVID-19 vaccine compared to those from BAME groups, those
202 from the highest education group are two and a half times more likely than those from the lowest
203 education group to accept it, and those in the highest income group are almost twice as likely to
204 accept the vaccine compared to those in the lowest income group.

205 Overall, those most at risk of the negative sequelae of COVID-19 had less intentions to get
206 vaccinated than those at lower risk [22]. For example, intention was higher in participants of white
207 ethnicity in comparison to BAME groups. However, it should be noted that this binary approach to
208 looking at differences in ethnicity is problematic, as it may mask important differences between
209 diverse racialised and minoritised communities with distinct cultures and social norms. We also
210 found that intentions for vaccination were higher in those with higher levels of income, again raising
211 questions about why those most likely to suffer the negative consequences of COVID-19 would be
212 the least likely to intend to vaccinate. These findings fit with the emerging literature on COVID-19
213 vaccine acceptance which suggests that those from BAME groups may be less likely to accept a
214 vaccine [17] and that COVID-19 vaccine hesitancy is more prevalent in those with lower income [19].
215 If these inequalities in intention translate into uptake then these findings are very important as they
216 suggest the likelihood that vaccination programmes, unless implemented with targeted and tailored
217 interventions to enhance vaccination rates, may actually amplify existing inequalities. More
218 positively, intention to accept a COVID-19 vaccine was higher among those who were shielding (i.e.
219 those who had been classified as high risk based on underlying health conditions or age).

220 Together, these initial studies highlight the need for government and public health bodies to
221 think carefully about how to approach their publics with further demands for behavioural change
222 (i.e., uptake of a COVID-19 vaccine). The findings here suggest, for example, that a 'one size fits all'
223 approach to mass media interventions represents at best a partial solution to increasing vaccination
224 uptake and at worst, a solution that backfires, amplifying existing inequalities. These findings
225 suggest that future interventions need to be targeted to a range of sub-populations and diverse
226 communities [23, 24]. The range of interventions should offer different kinds of educational,
227 persuasive or enabling approaches [25] to different groups of people and there is growing
228 recognition that such interventions should be co-produced. Issues of visual cultural representation,
229 identifiable local key opinion leaders, readability and reading levels, and trust will all be important
230 considerations. These emerging findings also lend themselves to considering the wider
231 opportunities to targeting afforded by social media. Whilst marketing and politics are capitalising on
232 these new opportunities, it is less clear if and how public health can do so. Equally these initial
233 findings also suggest that health care professionals should be trained to anticipate and respond to
234 diverse segments of the population differently with overt and inclusive demonstrations of cultural
235 competencies.

236 If we imagine a future of targeted interventions to improve COVID-19 vaccination uptake, it is
237 also important to focus now on the granularity of messaging that will shortly be needed. Whilst
238 evidence is emerging concerning where and amongst whom interventions need to be targeted, it is
239 currently unclear how intervention content should be tailored to these populations and communities
240 and their particular beliefs. We need to use the full range of social and behavioural sciences now to
241 address this key gap and ensure that we are prepared and ready to support the whole population in
242 gaining maximum benefit from available vaccines. One preliminary study in this area used the
243 Behaviour Change Wheel [26-28] to provide recommendations for the design of interventions aimed
244 at maximising public acceptance of COVID-19 vaccine. The findings suggested that interventions

245 should utilise the behaviour change techniques [29] of information about health, emotional, social
246 and environmental consequences, and salience of consequences in order to provide the public with
247 information about the beneficial consequences for themselves and for others [30]. Further, more
248 in-depth research like this which focuses on intervention development is required.

249 Strengths of the current study include the large sample size, the use of two waves of data
250 collection to examine stability in COVID-19 vaccination intention and the inclusion of a range of
251 sociodemographic factors to allow us to understand the social patterning of COVID-19 vaccination
252 acceptance. However, it is important to note that the study is not nationally representative, and
253 weighting was applied to the gender and education variables due to the under-representation of
254 males and those with lower levels of education. Furthermore, we experienced a participant
255 drop-out rate of 41% from time one to time two meaning that we cannot draw any conclusions about
256 the change in COVID-19 vaccination intention in those participants who were lost at follow-up.
257 Moreover, we experienced higher dropout in those with lower education levels, males, and in the
258 younger age group. In addition, participants were answering about their intention to accept a
259 hypothetical COVID-19 vaccine, without information regarding the specifics of the vaccine in terms
260 of number of doses needed, potential side-effects, or prioritisation of delivery across the population.
261 All of which may influence eventual uptake of a COVID-19 vaccination.

262 5. Conclusions

263 Intention to accept a COVID-19 vaccine is currently high in Scotland and our findings suggest
264 that intention to receive the vaccine did not fall in the context of lower infection rates and fewer
265 restrictions. However, the data also point to a sizable minority of the public who are hesitant about
266 receiving a future COVID-19 vaccine. Of note, intention was higher in participants of white ethnicity
267 in comparison to those from BAME groups, and in those with higher levels of income and education.
268 Our findings and those from other studies suggest that future interventions need to be targeted to a
269 range of sub-populations and diverse communities. To do so, we need to better understand the
270 barriers to vaccination in these groups so that we can collectively be better prepared to deliver
271 appropriate evidence-based culturally and community-appropriate messaging aimed at maximising
272 COVID-19 vaccine uptake.

273 **Author Contributions:** Conceptualization, L.W. and P.F.; methodology, L.W. and L.R.; formal analysis, J.M. and
274 D.Y.; investigation, L.R.; writing—original draft preparation, L.W., P.F., J.M.; writing—review and editing, all
275 authors.; funding acquisition, L.W. and P.F. All authors have read and agreed to the published version of the
276 manuscript. The CATALYST project team: Leanne Fleming, Xanne Janssen, Alison Kirk, Madeleine Grealy,
277 Bradley MacDonald.

278 **Funding:** This research was funded by the Chief Scientist Office in Scotland (Ref COV/SCL/20/09).

279 **Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the
280 study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to
281 publish the results.

282 References

- 283 1. de Figueiredo, A.; Simas, C.; Karafillakis, E.; Paterson, P.; Larson, H.J. Mapping global trends in vaccine
284 confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling
285 study. *Lancet* **2020**, *396*, 898–908. [https://doi.org/10.1016/S0140-6736\(20\)31558-0](https://doi.org/10.1016/S0140-6736(20)31558-0)
- 286 2. Larson, H.J.; De Figueiredo, A.; Xiahong, Z.; Schulz, W.S.; Verger, P.; Johnston, I.G.; ... Jones, N.S. The
287 state of vaccine confidence 2016: Global insights through a 67-country survey. *EBioMedicine* **2016**, *12*,
288 295–301. <https://doi.org/10.1016/j.ebiom.2016.08.042>
- 289 3. Wellcome Trust. Wellcome Global Monitor 2018. Available online
290 <https://wellcome.ac.uk/reports/wellcome-global-monitor/2018> (accessed on 20th November 2020).
- 291 4. Jorgensen, P.; Mereckiene, J.; Cotter, S.; Johansen, K.; Tsoлова, S.; Brown, C. How close are countries of
292 the WHO European Region to achieving the goal of vaccinating 75% of key risk groups against influenza?
293 Results from national surveys on seasonal influenza vaccination programmes, 2008/2009 to 2014/2015.
294 *Vaccine* **2018**, *36*, 442–452. <https://doi.org/10.1016/j.vaccine.2017.12.019>

- 295 5. MacDonald, N.E.; & the SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: Definition,
296 scope and determinants. *Vaccine* **2015**, *33*, 4161–4164. <https://doi.org/10.1016/j.vaccine.2015.04.036>
- 297 6. Lane, S.; MacDonald, N.E.; Marti, M.; & Dumolard, L. Vaccine hesitancy around the globe: analysis of
298 three years of WHO/UNICEF Joint Reporting Form data—2015–2017. *Vaccine* **36**, 3861–3867 (2018).
- 299 7. Larson, H.J.; Jarrett, C.; Eckersberger, E.; Smith, D.M.D.; & Paterson, P. Understanding vaccine hesitancy
300 around vaccines and vaccination from a global perspective: a systematic review of published literature,
301 2007–2012. *Vaccine* **2014**, *32*, 2150–2159. <https://doi.org/10.1016/j.vaccine.2014.01.081>
- 302 8. Brewer, N.T.; Chapman, G.B.; Rothman, A.J.; Leask, J.; & Kempe, A. Increasing vaccination: putting
303 psychological science into action. *Psychol Sci Public Interest* **2017**, *18*(3), 149–207.
304 <https://doi.org/10.1177/1529100618760521>
- 305 9. Schmid, P.; Rauber, D.; Betsch, C.; Lidolt, G.; & Denker, M.L. Barriers of influenza vaccination intention
306 and behavior—a systematic review of influenza vaccine hesitancy, 2005–2016. *PloS one* **2017**, *12*(1), e0170550.
307 <https://doi.org/10.1371/journal.pone.0170550>
- 308 10. Bish, A., Yardley, L., Nicoll, A., & Michie, S. Factors associated with uptake of vaccination against
309 pandemic influenza: A systematic review. *Vaccine* **2011**, *29*, 6472–6484.
310 <https://doi.org/10.1016/j.vaccine.2011.06.107>
- 311 11. Brien, S.; & Kwong, J. C. The determinants of 2009 pandemic A/H1N1 influenza vaccination: A systematic
312 review. *Vaccine* **2012**, *30*, 1255–1264. <https://doi.org/10.1016/j.vaccine.2011.12.089>
- 313 12. Fabry, P.; Gagneur, A.; & Pasquier, J.-C. Determinants of A(H1N1) vaccination: cross sectional study in a
314 population of pregnant women in Quebec. *Vaccine* **2011**, *29*, 1824–1829.
315 <https://doi.org/10.1016/j.vaccine.2010.12.109>
- 316 13. Han, K. Y. J.; Michie, S.; Potts, H.W.; & Rubin, G.J. Predictors of influenza vaccine uptake during the
317 2009/10 influenza A H1N1v ('swine flu') pandemic: Results from five national surveys in the United
318 Kingdom. *Prev Med* **2016**, *84*, 57–61. <https://doi.org/10.1016/j.ypmed.2015.12.018>
- 319 14. Seale, H.; Heywood, A.E.; McLaws, M.L.; Ward, K.F.; Lowbridge, C.P.; Van, D.; & MacIntyre, C.R. Why
320 do I need it? I am not at risk! Public perceptions towards the pandemic (H1N1) 2009 vaccine. *BMC Infect*
321 *Dis* **2010**, *99*. <https://doi.org/10.1186/1471-2334-10-99>
- 322 15. Lazarus, J.V.; Ratzan, S.C.; Palayew, A.; Gostin, L.O.; Larson, H.J.; Rabin, K.; Kimball, S., & El-Mohandes,
323 A. A global survey of potential acceptance of a COVID-19 vaccine. *Nature Medicine* **2020**.
324 <https://doi.org/10.1038/s41591-020-1124-9>
- 325 16. Rhodes, A.; Hoq, M.; Measey, M-A.; Danchin, M. Intention to vaccinate against COVID-19 in Australia.
326 *Lancet Infect Dis* **2020**. [https://doi.org/10.1016/S1473-3099\(20\)30724-6](https://doi.org/10.1016/S1473-3099(20)30724-6)
- 327 17. Malik, A.M.; McFadden, S.M.; Elharake, J.; Omer, S.B. Determinants of COVID-19 vaccine acceptance in
328 the US. *EClinical Medicine* **2020**. <https://doi.org/10.1016/j.eclinm.2020.100495>
- 329 18. IPSOS MORI: News Three in four adults globally say they would get a vaccine for COVID-19. Available
330 online:
331 <https://www.ipsos.com/ipsos-mori/en-uk/three-four-adults-globally-say-they-would-get-vaccine-covid-19>
332 9 (accessed on 10th November 2020).
- 333 19. The COCONEL Group. A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and
334 politicisation. *Lancet Infect Dis* **2020**, *20*, 769–70. [https://doi.org/10.1016/s1473-3099\(20\)30426-6](https://doi.org/10.1016/s1473-3099(20)30426-6)
- 335 20. Dodd, R.H.; Cvejic, E.; Bonner, C.; Pickles, K.; McCaffery, K.J.; Sydney Health Literacy Lab COVID-19
336 group. Willingness to vaccinate against COVID-19 in Australia. *Lancet Infect Dis* **2020**.
337 [https://doi.org/10.1016/S1473-3099\(20\)30559-4](https://doi.org/10.1016/S1473-3099(20)30559-4)
- 338 21. Bartsch, S.M.; et al. Vaccine efficacy needed for a COVID-19 coronavirus vaccine to prevent or stop an
339 epidemic as the sole intervention. *Am J Prev Med* **2020**, *59*, 493–503.
340 <https://doi.org/10.1016/j.amepre.2020.06.011>
- 341 22. Office for National Statistics Deaths involving COVID-19 by local area and socioeconomic deprivation:
342 deaths occurring between 1 March and 31 July 2020. Available online:
343 <https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsinvolvingcovid19bylocalareasanddeprivation/deathsoccurringbetween1marchand31july2020>
344 (accessed on 12th November 2020).
- 345 23. Dube, E.; Leask, J.; Wolff, B.; Hickler, B.; Balaban, V.; Hosein, E.; Habersaat, K. The WHO Tailoring
346 Immunization Programmes (TIP) approach: Review of implementation to date. *Vaccine* **2018**, *36*,
347 1509–1515. <https://doi.org/10.1016/j.vaccine.2017.12.012>
348

- 349 24. Thomson, A.; Vallée-Tourangeau, G.; & Suggs, L.S. Strategies to increase vaccine acceptance and uptake:
350 from behavioral insights to context-specific, culturally-appropriate, evidence-based communications and
351 interventions. *Vaccine* **2018**, *36*, 6457–6458. <https://doi.org/10.1016/j.vaccine.2018.08.031>
- 352 25. Dube, E.; Gagnon, D.; MacDonald, N.E.; the SAGE Working Group on Vaccine Hesitancy. Strategies
353 intended to address vaccine hesitancy: Review of published reviews. *Vaccine* **2015**, *33*, 4191-4203.
354 <https://doi.org/10.1016/j.vaccine.2015.04.041>
- 355 26. Michie, S.; Atkins, L.; & West, R. *The behaviour change wheel: A guide to designing interventions*. London, UK:
356 Silverback, 2014.
- 357 27. Michie, S.; Stralen, M. M.; West, R. The behaviour change wheel: A new method for characterising and
358 designing behaviour change interventions. *Implement Sci* **2011**, *6*, 42.
359 <https://doi.org/10.1186/1748-5908-6-42>
- 360 28. Cane, J.; O'Connor, D.; & Michie, S. Validation of the theoretical domains framework for use in behaviour
361 change and implementation research. *Implement Sci* **2012**, *7*, 37. <https://doi.org/10.1186/1748-5908-7-37>
- 362 29. Michie, S.; Richardson, M.; Johnston, M.; Abraham, C.; Francis, J.; Hardeman, W.; . . . Wood, C. E. (2013).
363 The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: Building an
364 international consensus for the reporting of behavior change interventions. *Ann Behav Med* **2013**, *46*, 81–95.
365 <https://doi.org/10.1007/s12160-013-9486-6>
- 366 30. Williams, L.; Gallant, A.J.; Rasmussen, S.; Brown Nicholls, L.A.; Cogan, N.; Deakin, K.; Young, D.;
367 Flowers, P. Towards intervention development to increase the uptake of COVID-19 vaccination among
368 those at high risk: Outlining evidence-based and theoretically informed future intervention content. *Br J*
369 *Health Psychol* **2020**, *25*, 1039-1054. <https://doi.org/10.1111/bjhp.12468>

370 **Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional
371 affiliations.



© 2020 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).

372